financetom
Business
financetom
/
Business
/
Grifols says founding family, Brookfield looking to delist drugmaker
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Grifols says founding family, Brookfield looking to delist drugmaker
Jul 8, 2024 1:08 AM

MADRID, July 8 (Reuters) - The Grifols family and

Canadian fund Brookfield have agreed to launch a joint takeover

bid for Spanish drugmaker Grifols with the intent to

delist it, the company said in a regulatory filing on Monday.

Grifols said its board held an extraordinary meeting over

the weekend to study a preliminary offer presented by Brookfield

and the founding family, which has a nearly 30% stake.

They asked the board for access to certain company

information for due diligence before potentially buying all of

Grifols' shares, it said.

The company said it did not know if a transaction will take

place and the terms in which it could be carried out.

Shares in Grifols were suspended from trading on the

blue-chip index by regulator CNMV shortly before the

market opened. Traders had expected the shares to rise between

8% and 10%.

The founding family's aim was to gain access to the

company's books to make a final offer in the coming weeks,

business newspaper Cinco Dias reported on Sunday, adding that

Lazard ( LAZ ) was the sole financial advisor to both parties.

The deal could be worth around 5.5 billion euros ($5.96

billion), according to the report.

Brookfield's European office in London was not immediately

available for comment on Monday.

Grifols' main shareholders - after the descendants of three

brothers who took the company from a small family-owned lab in

Barcelona to a global player in the plasma derivatives business

- include the funds Capital, BlackRock ( BLK ), Europacific and Rokos

Global.

Since early January, short-seller fund Gotham City Research

has released several reports accusing Grifols of overstating

earnings and understating debt. Its market value has shed

several billion euros since then.

Following the reports, Grifols announced governance changes

and revised its reported leverage higher after market supervisor

CNMV required that it change its calculations.

Last week, Grifols appointed Rahul Srinivasan as chief

financial officer in a management reshuffle and Scranton

Enterprises, an entity tied to the Grifols family, reached an

agreement with a private investor to refinance 377 million euros

of debt in one of its units.

($1 = 0.9229 euros)

(Reporting by David Latona; Additional reporting by Marta

Serafinko; Editing by Louise Heavens and Arun Koyyur)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Australia takes Microsoft to court, says it misled 2.7 million customers
Australia takes Microsoft to court, says it misled 2.7 million customers
Oct 26, 2025
(Reuters) -Australia's competition watchdog said on Monday said it has filed proceedings in the Federal Court against Microsoft Australia and its parent company Microsoft Corp ( MSFT ) for allegedly misleading about 2.7 million Australian customers. The Australian Competition and Consumer Commission (ACCC) alleges that the company misled customers about subscription options and price increases, after it integrated its AI assistant,...
Australia's Larvotto Resources rejects $373 million takeover offer on valuation concerns
Australia's Larvotto Resources rejects $373 million takeover offer on valuation concerns
Oct 26, 2025
(Reuters) -Australia's Larvotto Resources ( LRVTF ) said on Monday it had rejected a non-binding indicative offer received last week from United States Antimony Corporation, valuing the miner at about A$722.9 million ($469.74 million). The diversified miner said at the time, USAC's five-day volume-weighted average price had implied an offer value of A$1.40 per Larvotto share. However, as of Friday, the...
Drug developer MapLight Therapeutics valued at $704.3 million after US IPO
Drug developer MapLight Therapeutics valued at $704.3 million after US IPO
Oct 26, 2025
Oct 26 (Reuters) - Drug developer MapLight Therapeutics, backed by controlling shareholder Novo Holdings, is valued at $704.3 million after its Nasdaq debut on Sunday, as biotech IPOs show signs of revival following a months-long freeze. The Redwood City, California-based company sold 14.75 million shares in the initial public offering to raise $250.8 million. The company priced the offering at...
HSBC to book $1.1 billion provision after Luxembourg court ruling in Madoff case
HSBC to book $1.1 billion provision after Luxembourg court ruling in Madoff case
Oct 26, 2025
(Reuters) -HSBC Holdings ( HSBC ) said on Monday it will recognise a provision of $1.1 billion in its third-quarter results after a Luxembourg court ruling in a long-running lawsuit tied to the Bernard Madoff investment fraud. HSBC ( HSBC ) became entangled in the Madoff scandal through its role as service provider to several funds that invested with Bernard...
Copyright 2023-2026 - www.financetom.com All Rights Reserved